Tegoprazan matched lansoprazole for preventing NSAID-related peptic ulcers over 24 weeks

Source

Source: No uploaded documents or extracted text were provided.

Phase III evidence supports tegoprazan as an effective gastroprotective option for patients continuing long-term NSAID therapy.

Why it matters

Long-term NSAID use increases the risk of gastric and duodenal ulcers, creating a need for reliable prevention.

Study snapshot

Randomized, double-blind, active-controlled, multicenter Phase III trial conducted over up to 24 weeks.

Treatments

Tegoprazan 25 mg was compared with lansoprazole 15 mg in patients continuing NSAIDs.

392

Patients randomized

269

Included in the per-protocol analysis

Hero fact

Tegoprazan was non-inferior to lansoprazole for preventing gastroduodenal ulcers at week 24.

Non-inferiority p = 0.0004

Efficacy and symptoms

Endpoint	Finding	Direction
Peptic ulcer prevention at week 24	Tegoprazan 25 mg was as effective as lansoprazole 15 mg	Non-inferior; p = 0.0004
Heartburn-free rate at week 12	Higher with tegoprazan	Favored tegoprazan
Other NSAID-related GI symptom-free rates	No significant difference between groups	Comparable

Safety profile

Safety measure	Comparison	Interpretation
Adverse drug reactions	Tegoprazan vs lansoprazole	Comparable tolerability
Serious adverse events	Assessed across both groups	No safety disadvantage highlighted

Takeaway

Tegoprazan is a clinically effective alternative for gastroprotection in patients requiring long-term NSAID therapy, with safety and tolerability comparable to lansoprazole.

👀 View Mode